Tag Archives: Food and Drug Administration

FDA Approves Avastin for New Second-Line Use

For patients with metastatic colorectal cancer, the Food and Drug Administration (FDA) has approved a new use of Avastin® (bevacizumab): It can be continued as part of ‘second-line’ combination therapy, even if it was used in first-line therapy. When stage IV cancer progresses despite use of Avastin plus either FOLFOX (5FU plus Eloxatin® or oxalyplatin) or FOLFIRI (5FU plus Camptosar® or irinotecan)-based chemotherapy, the FDA has now approved continued use of Avastin when second-line treatment switches to the other chemotherapy. Avastin is a monoclonal antibody (a “targeted drug”) that helps prevent a cancer from stimulating growth of new blood-vessels that then help the tumor get bigger. The FDA’s approval is based on a large, randomized

Watch our Webinar on Drug Shortages

On Wednesday night, Dr. Lindsey Poppe, the Pharmacy Clinical Manager for Oncology for the University of North Carolina hospital system talked about the alternatives and options that patients have when directly faced with the current chemo drug shortage. You can watch a recording of the webinar on our website, along with all of our past patient webinars. Webinar: What to Do When Your Doc is Out of 5-FU from Fight Colorectal Cancer on Vimeo.

Top